Current Cancer Biomarkers

Tumour DNA Sequencing

Author(s): Farhadul Islam *

Pp: 81-99 (19)

DOI: 10.2174/9789815079364123010008

* (Excluding Mailing and Handling)


Cancer pathogenesis is a multistep process involving the accumulation of complex genetic and epigenetic alterations. The disease can be sporadic or familial in nature. The genes associated with much familial cancer or inherited cancer susceptible syndrome have already been identified. Thus, genetic testing for pathogenic variants of these genes could predict whether an individual has a high risk of developing cancer in their lifetime. Also, tumour DNA sequencing in patients with cancer can be used for therapy selection and to predict treatment outcomes. The recent development of high throughput sequencing enables the exploration of whole genome profiling, including mutations, structural variations, transcriptomes, splicing events, etc., in patients with cancer, thereby providing guidelines for personalized precision medicine in clinical practice. However, the translation of cancer genome sequencing information into the clinical treatment plan is highly complicated, needs multidisciplinary expert panels and is not cost-effective for mass application. Further development in sequencing analysis and data interpretation are imperative for point-of-care settings applications. This chapter outlines the clinical significance of tumour DNA testing and genomic sequencing in various cancers.

Keywords: Tumour DNA, Genetic testing, Genomic sequencing, Cancer genome sequencing, High-throughput sequencing, Sporadic cancer, Familial cancer, Cancer predisposition, Structural variation, Somatic mutation, Hereditary cancer, Cancer syndrome, Breast cancer, Ovarian cancer, Colorectal cancer, Skin cancer, Prostate cancer, Lung cancer, Thyroid cancer, Pancreatic cancer, Next-generation sequencing.

Related Journals
Related Books
© 2024 Bentham Science Publishers | Privacy Policy